Cargando…

Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience

Subcutaneous apomorphine infusion is a device-aided therapy for Parkinson’s disease that can be considered when motor fluctuations become persistent and are no longer adequately controlled by oral/transdermal medication. Apomorphine infusion is less invasive than enteral levodopa, deep brain stimula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henriksen, Tove, Katzenschlager, Regina, Bhidayasiri, Roongroj, Staines, Harry, Lockhart, Donna, Lees, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645621/ https://www.ncbi.nlm.nih.gov/pubmed/37658155 http://dx.doi.org/10.1007/s00702-023-02686-7

Ejemplares similares

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Home initiation of apomorphine infusion: lessons from the COVID-19 pandemic and implications for current clinical practice
por: Kobylecki, Christopher, et al.
Publicado: (2023)

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study
por: Zagnoli, Fabien, et al.
Publicado: (2023)

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
por: Gaire, Suman, et al.
Publicado: (2021)

Continuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation
por: Henriksen, Tove, et al.
Publicado: (2021)

We Move or Are We Moved? Unpicking the Origins of Voluntary Movements to Better Understand Semivoluntary Movements
por: Virameteekul, Sasivimol, et al.
Publicado: (2022)

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review
por: Moes, Harmen R., et al.
Publicado: (2023)

Current and novel infusion therapies for patients with Parkinson's disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Botulinum Neurotoxin-A Injection in Adult Cervical Dystonia and Spastic Paresis: Results From the INPUT (INjection Practice, Usage and Training) Survey
por: Chung, Tae Mo, et al.
Publicado: (2020)

Cost-Effectiveness of Apomorphine Sublingual Film as an “On-Demand” Treatment for “OFF” Episodes in Patients with Parkinson’s Disease
por: Thach, Andrew, et al.
Publicado: (2021)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience
por: Băjenaru, O., et al.
Publicado: (2015)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Treating Disorders of Consciousness With Apomorphine: Protocol for a Double-Blind Randomized Controlled Trial Using Multimodal Assessments
por: Sanz, Leandro R. D., et al.
Publicado: (2019)

Genetic testing for Parkinson’s disease in clinical practice
por: Gasser, Thomas
Publicado: (2023)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity
por: Dressler, Dirk, et al.
Publicado: (2021)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
por: Regensburger, Martin, et al.
Publicado: (2023)

The heterogeneity of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2023)

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
por: Tönges, Lars, et al.
Publicado: (2022)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

Life style and Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2022)

Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease
por: Hagell, Peter, et al.
Publicado: (2020)

Treatment of Parkinson’s disease in the advanced stage
por: Ossig, C., et al.
Publicado: (2013)

Small intestine dysfunction in Parkinson’s disease
por: Dutkiewicz, Justyna, et al.
Publicado: (2015)

Neuroprotection in Parkinson’s disease: facts and hopes
por: Salamon, András, et al.
Publicado: (2019)

Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
por: Diaconu, Ştefania, et al.
Publicado: (2023)

Best practice approaches to outpatient management of people living with Parkinson’s disease during the COVID-19 pandemic
por: Demleitner, Antonia F., et al.
Publicado: (2022)

Sleep and non-motor symptoms in Parkinson’s disease
por: Maass, Antonia, et al.
Publicado: (2013)

Parkinson’s disease between internal medicine and neurology
por: Csoti, Ilona, et al.
Publicado: (2015)

Magnetic resonance imaging for the diagnosis of Parkinson’s disease
por: Heim, Beatrice, et al.
Publicado: (2017)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Disease modification in Parkinsonism: obstacles and ways forward
por: Höllerhage, M., et al.
Publicado: (2022)

The use of wearables for the diagnosis and treatment of Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2023)

Blood neurofilament light chain in Parkinson’s disease
por: Buhmann, Carsten, et al.
Publicado: (2023)

Parkinson’s disease therapy: what lies ahead?
por: Wolff, Andreas, et al.
Publicado: (2023)

Dementia spectrum disorders: lessons learnt from decades with PET research
por: Wilson, Heather, et al.
Publicado: (2019)

Non-motor symptoms of Parkinson’s disease: the patient’s perspective
por: Breen, Kieran C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2fid6d4vdp507i4tbn936o84fe